Sterile Fill Finish
Vial filling for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs.
Read MoreDrug Product Testing
Analytical & microbiological testing including raw materials, in-process controls, QC release & stability.
Read MoreQualified Person Release
QP release & GMP certification with QA review of every one of your batches.
Read MoreClinical Labeling & Packaging
Full packaging support for your product including bespoke design, printing and assembly to ensure its delivered on time & to specification.
Read MoreProduct Development
A range of product development services to get products from the pre-clinical phase into clinical trials.
Read MoreWHAT WE DO
We are a UK-based contract manufacturing organisation (CMO) that specialises in the GMP manufacture and sterile fill-finish of vials for clinical trials and low volume commercial supply.
Our biologic and small molecule production capabilities support biotech and pharmaceutical companies across the world that require injectable products.
STERILE FILL-FINISH
Our facility was purpose-built to meet increasing market demand for small-scale, shorter sterile drug product development timelines, while consistently maintaining regulatory compliance.
We reliably support our customers with the aseptic filling and lyophilisation of conventional, biologic and cytotoxic drugs into vials. Helping clients across the globe meet their project milestones, we provide rapid access to manufacturing slots and quick release of drug product to ensure tight timelines are successfully met.
STIRLING SERVICE
We built our facility at the Innovation Park in Stirling in 2011 with technical capability, quality assurance and operational flexibility at its core. Its design gives you quick access to production slots to progress batch release in less time, without any compromise on quality.
Manufacturing takes place within a purpose-built MHRA-licensed and FDA inspected facility, enabling us to fill bulk volumes <100 litres. This includes products such as monoclonal antibodies (mAbs), proteins, peptides, Ribonucleic Acid (RNA), cytotoxic, cytostatic and high potent APIs including antibody drug conjugates (ADCs).
News
SYMBIOSIS AFFIRMS COMMITMENT TO GROWTH WITH NEW BUSINESS DEVELOPMENT MANAGER FOR THE NORDICS AND GERMANY
Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines,… Read More
Events
Tides USA 2021
Symbiosis Pharmaceutical Services is happy to announce that we will be attending this year’s Tides USA… Read More
Blog
The Scottish Life Sciences Covid-19 Strategic Response Plan
Symbiosis CEO Colin MacKay is a proud member of the ILG (Life Sciences Industry Leadership Group)… Read More
